Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selective treatment in advanced colorectal cancer: choice of capecitabine or 5-fluorouracil with oxaliplatin or irinotecan plus bevacizumab as first-line chemotherapy
2009-012562-31Phase 2Completed
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Jul 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of bevacizumab in colorectal cancer (CRC) (2 arms), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoint: progression-free survival. Started Jul 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2009-012562-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012562-31.